Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

[1]  G. Morgan,et al.  The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. , 2012, Blood.

[2]  B. Pégourié,et al.  Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. , 2011, Blood.

[3]  B. Pégourié,et al.  Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program , 2011 .

[4]  M. Dimopoulos,et al.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. , 2011, Blood.

[5]  D. Esseltine,et al.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.

[6]  M. Baccarani,et al.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.

[7]  J. Miguel,et al.  A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib , 2010 .

[8]  P. Moreau,et al.  Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02. , 2010 .

[9]  K. Owzar,et al.  Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104 , 2010 .

[10]  M. Kersten,et al.  HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM) , 2010 .

[11]  P. Moreau,et al.  Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Mohty,et al.  Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Esseltine,et al.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.

[14]  J. Crowley,et al.  Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Chanan-Khan,et al.  Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Boccadoro,et al.  Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Sonneveld,et al.  A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. , 2010, Blood.

[18]  M. Boccadoro,et al.  Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Baccarani,et al.  Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Avet-Loiseau,et al.  The role of complete response in multiple myeloma. , 2009, Blood.

[21]  J. Harousseau Maintenance therapy in multiple myeloma , 2009, Hematology Reviews.

[22]  D. Reece,et al.  A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. , 2008, Cancer treatment reviews.

[23]  H. van de Velde,et al.  Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma , 2007, Haematologica.

[24]  M. Baccarani,et al.  Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[26]  John Crowley,et al.  Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. , 2006, Blood.

[27]  M. Baccarani,et al.  Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. , 2005, Blood.

[28]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[30]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[31]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[32]  B. Barlogie,et al.  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.

[33]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[34]  N. Nahi,et al.  Improved progression free survival with bortezomib consolidation after high dose melphalan: results of a randomised phase III trial , 2011 .

[35]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2007, Leukemia.

[36]  J. Rossi,et al.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.